Video

Rituximab, Obinutuzumab, and Ofatumumab in CLL

For High-Definition, Click

At this point, there are 3 anti-CD20 monoclonal antibodies approved as treatments for patients with chronic lymphocytic leukemia (CLL): rituximab (Rituxan), obinutuzumab (Gazyva), and ofatumumab (Arzerra), states Myron Czuczman, MD. Although they all target CD20, these 3 agents have different mechanisms of action, different structures, and functions.

Rituximab is a class I chimeric anti-CD20 antibody that induces both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), and may also be involved in direct signaling. Obinutuzumab, also known as GA101, is a class II CD20 antibody. It is more effective than rituximab at eliciting ADCC but has very little impact on CDC. Ofatumumab is a fully human monoclonal antibody that was designed to have superior CDC to rituximab. The treatment also possesses ADCC activity.

Obinutuzumab was designed to work when effector cells are more intact, says Czuczman. For example, individuals with end-stage disease who have received 3 to 4 cycles of different therapies may not have as robust of an immune system or complete effector cells as newly diagnosed, untreated individuals. In contrast to obinutuzumab, which was designed to work with effector cells, ofatumumab was meant to target complement cells, which may not be as depleted in patients with end-stage disease who have received many lines of therapy. This mechanism makes ofatumumab preferred in the later course of therapy, notes Czuczman.

Related Videos
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss ongoing research to watch in acute lymphoblastic leukemia.
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss how to incorporate blinatumomab into clinical practice for ALL.
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss adverse effect management in acute lymphoblastic leukemia.
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss data for blinatumomab plus chemotherapy in newly diagnosed pediatric ALL.
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss first-line treatment considerations for pediatric ALL.
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, on blinatumomab as consolidation therapy in older patients with newly diagnosed ALL.
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, on alloHCT outcomes from the ECOG ACRIN E1910 trial of blinatumomab.
Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)